Advertisement

Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes

  • Steven J. Conrad
  • Jia LiuEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1937)

Abstract

Treatments with poxvirus vectors can have long-lasting immunological impact in the host, and thus they have been extensively studied to treat diseases and for vaccine development. More importantly, the oncolytic properties of poxviruses have led to their development as cancer therapeutics. Two poxviruses, vaccinia virus (VACV) and myxoma virus (MYXV), have been extensively studied as virotherapeutics with promising results. Vaccinia virus vectors have advanced to the clinic and have been tested as oncolytic therapeutics for several cancer types with successes in phase I/II clinical trials. In addition to oncolytic applications, MYXV has been explored for additional applications including immunotherapeutics, purging of cancer progenitor cells, and treatments for graft-versus-host diseases. These novel therapeutic applications have encouraged its advancement into clinical trials. To meet the demands of different treatment needs, VACV and MYXV can be genetically engineered to express therapeutic transgenes. The engineering process used in poxvirus vectors can be very different from that of other DNA virus vectors (e.g., the herpesviruses). This chapter is intended to serve as a guide to those wishing to engineer poxvirus vectors for therapeutic transgene expression and to produce viral preparations for preclinical studies.

Key words

Poxvirus Poxvirus genetic engineering Vaccinia virus (VACV) Myxoma virus (MYXV) Infection/transfection Transgene expression Poxvirus transfer vector 

References

  1. 1.
    FDA guidance for industry: gene therapy clinical trials - observing subjects for delayed adverse events (2006)Google Scholar
  2. 2.
    Fenner F, Henderson D, Arita I et al (1988) Smallpox and its eradication. In: Smallpox and its eradication, vol 6. World Health Organization, GenevaGoogle Scholar
  3. 3.
    Stewart AJ, Devlin PM (2006) The history of the smallpox vaccine. J Infect 52(5):329–334.  https://doi.org/10.1016/j.jinf.2005.07.021CrossRefPubMedGoogle Scholar
  4. 4.
    La Scola B, Audic S, Robert C et al (2003) A giant virus in amoebae. Science 299(5615):2033.  https://doi.org/10.1126/science.1081867CrossRefPubMedGoogle Scholar
  5. 5.
    Smith GL, Moss B (1983) Infectious poxvirus vectors have capacity for at least 25,000 base-pairs of foreign DNA. Gene 25(1):21–28.  https://doi.org/10.1016/0378-1119(83)90163-4CrossRefPubMedGoogle Scholar
  6. 6.
    Evans DH, Stuart D, McFadden G (1988) High levels of genetic recombination among cotransfected plasmid DNAs in poxvirus-infected mammalian cells. J Virol 62(2):367–375PubMedPubMedCentralGoogle Scholar
  7. 7.
    Schramm B, Locker JK (2005) Cytoplasmic organization of POXvirus DNA replication. Traffic 6(10):839–846.  https://doi.org/10.1111/j.1600-0854.2005.00324.xCrossRefPubMedGoogle Scholar
  8. 8.
    Yang Z, Martens CA, Bruno DP et al (2012) Pervasive initiation and 3′-end formation of poxvirus postreplicative RNAs. J Biol Chem 287(37):31050–31060.  https://doi.org/10.1074/jbc.M112.390054CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kotwal GJ, Abrahams M-R (2004) Growing poxviruses and determining virus titer. In: Vaccinia virus and poxvirology. Springer, Berlin, pp 101–112CrossRefGoogle Scholar
  10. 10.
    Smallwood SE, Rahman MM, Smith DW et al (2010) Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol Chapter 14:Unit 14A 11.  https://doi.org/10.1002/9780471729259.mc14a01s17CrossRefGoogle Scholar
  11. 11.
    Chan WM, Rahman MM, McFadden G (2013) Oncolytic myxoma virus: the path to clinic. Vaccine 31(39):4252–4258.  https://doi.org/10.1016/j.vaccine.2013.05.056CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bell J (2014) Oncolytic viruses: immune or cytolytic therapy? Mol Ther 22(7):1231–1232.  https://doi.org/10.1038/mt.2014.94CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Devaud C, John LB, Westwood JA et al (2013) Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2(8):e25961.  https://doi.org/10.4161/onci.25961CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9(1):64–71.  https://doi.org/10.1038/nrc2545CrossRefPubMedGoogle Scholar
  15. 15.
    Kirn DH, Wang Y, Le Boeuf F et al (2007) Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4(12):e353.  https://doi.org/10.1371/journal.pmed.0040353CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Li J, O'Malley M, Urban J et al (2011) Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 19(4):650–657.  https://doi.org/10.1038/mt.2010.312CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Seubert CM, Stritzker J, Hess M et al (2011) Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a beta-galactosidase-activatable prodrug seco-analog of duocarmycin SA. Cancer Gene Ther 18(1):42–52.  https://doi.org/10.1038/cgt.2010.49CrossRefPubMedGoogle Scholar
  18. 18.
    Zajac P, Oertli D, Marti W et al (2003) Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 14(16):1497–1510.  https://doi.org/10.1089/104303403322495016CrossRefPubMedGoogle Scholar
  19. 19.
    Loya SM, Zhang X (2015) Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther 22(3):237–246.  https://doi.org/10.1038/gt.2014.113CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rojas JJ, Sampath P, Bonilla B et al (2016) Manipulating TLR signaling increases the anti-tumor T cell response induced by viral cancer therapies. Cell Rep 15(2):264–273.  https://doi.org/10.1016/j.celrep.2016.03.017CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Conrad SJ, El-Aswad M, Kurban E et al (2015) Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice. J Exp Clin Cancer Res 34(1):19.  https://doi.org/10.1186/s13046-015-0131-zCrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mansfield DC, Kyula JN, Rosenfelder N et al (2016) Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther 23(4):357–368.  https://doi.org/10.1038/gt.2016.5CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang Q, Yu YA, Wang E et al (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67(20):10038–10046.  https://doi.org/10.1158/0008-5472.can-07-0146CrossRefPubMedGoogle Scholar
  24. 24.
    Wennier ST, Liu J, Li S et al (2012) Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther 20(4):759–768.  https://doi.org/10.1038/mt.2011.293CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wennier ST, Liu J, McFadden G (2012) Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr Pharm Biotechnol 13(9):1817–1833CrossRefGoogle Scholar
  26. 26.
    Yu F, Wang X, Guo ZS et al (2014) T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 22(1):102–111.  https://doi.org/10.1038/mt.2013.240CrossRefPubMedGoogle Scholar
  27. 27.
    Nounamo B, Liem J, Cannon M et al (2017) Myxoma virus optimizes cisplatin for the treatment of ovarian cancer in vitro and in a syngeneic murine dissemination model. Mol Ther Oncolytics 6:90–99.  https://doi.org/10.1016/j.omto.2017.08.002CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wilkinson MJ, Smith HG, McEntee G et al (2016) Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. Oncotarget 7(49):81208–81222.  https://doi.org/10.18632/oncotarget.12820CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cripe TP, Ngo MC, Geller JI et al (2015) Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 23(3):602–608.  https://doi.org/10.1038/mt.2014.243CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Park BH, Hwang T, Liu TC et al (2008) Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9(6):533–542CrossRefGoogle Scholar
  31. 31.
    Merrick AE, Ilett EJ, Melcher AA (2009) JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 10(12):1372–1382PubMedGoogle Scholar
  32. 32.
    Gentschev I, Muller M, Adelfinger M et al (2011) Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 6(7):e22069.  https://doi.org/10.1371/journal.pone.0022069CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Liu J, Wennier S, McFadden G (2010) The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect 12(14–15):1144–1152.  https://doi.org/10.1016/j.micinf.2010.08.012CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    McFadden G (2015) The curious road from basic pathogen research to clinical translation. PLoS Pathog 11(6):e1004997.  https://doi.org/10.1371/journal.ppat.1004997CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    McFadden G (2005) Poxvirus tropism. Nat Rev Microbiol 3(3):201–213.  https://doi.org/10.1038/nrmicro1099CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lun XQ, Yang WQ, Alain T et al (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 65(21):9982–9990.  https://doi.org/10.1158/0008-5472.Can-05-1201CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Stanford MM, Barrett JW, Nazarian SH et al (2007) Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 81(3):1251–1260.  https://doi.org/10.1128/JVI.01408-06CrossRefPubMedGoogle Scholar
  38. 38.
    Stanford MM, Shaban M, Barrett JW et al (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16(1):52–59.  https://doi.org/10.1038/sj.mt.6300348CrossRefPubMedGoogle Scholar
  39. 39.
    Tosic V, Thomas DL, Kranz DM et al (2014) Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PLoS One 9(10):e109801.  https://doi.org/10.1371/journal.pone.0109801CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Urbasic AS, Hynes S, Somrak A et al (2012) Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene. Am J Vet Res 73(8):1252–1261.  https://doi.org/10.2460/ajvr.73.8.1252CrossRefPubMedGoogle Scholar
  41. 41.
    MacNeill AL, Moldenhauer T, Doty R et al (2012) Myxoma virus induces apoptosis in cultured feline carcinoma cells. Res Vet Sci 93(2):1036–1038.  https://doi.org/10.1016/j.rvsc.2011.10.016CrossRefPubMedGoogle Scholar
  42. 42.
    Lun XQ, Zhou H, Alain T et al (2007) Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 67(18):8818–8827.  https://doi.org/10.1158/0008-5472.Can-07-1214CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Bartee MY, Dunlap KM, Bartee E (2016) Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells. Clin Lymphoma Myeloma Leuk 16(4):203–212.  https://doi.org/10.1016/j.clml.2015.12.005CrossRefPubMedGoogle Scholar
  44. 44.
    Bartee E, Chan WM, Moreb JS et al (2012) Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Tr 18(10):1540–1551.  https://doi.org/10.1016/j.bbmt.2012.04.004CrossRefGoogle Scholar
  45. 45.
    Lilly CL, Villa NY, Lemos de Matos A et al (2017) Ex vivo oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft versus tumor. Mol Ther Oncolytics 4:31–40.  https://doi.org/10.1016/j.omto.2016.12.002CrossRefPubMedGoogle Scholar
  46. 46.
    Gammon DB, Evans DH (2009) The 3′-to-5′ exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination. J Virol 83(9):4236–4250.  https://doi.org/10.1128/JVI.02255-08CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Shuman S (1991) Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro. J Biol Chem 266(17):11372–11379PubMedGoogle Scholar
  48. 48.
    Shuman S (1992) Two classes of DNA end-joining reactions catalyzed by vaccinia topoisomerase I. J Biol Chem 267(24):16755–16758PubMedGoogle Scholar
  49. 49.
    Petersen BO, Shuman S (1997) DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate. Nucleic Acids Res 25(11):2091–2097CrossRefGoogle Scholar
  50. 50.
    Garcia AD, Otero J, Lebowitz J et al (2006) Quaternary structure and cleavage specificity of a poxvirus holliday junction resolvase. J Biol Chem 281(17):11618–11626.  https://doi.org/10.1074/jbc.M600182200CrossRefPubMedGoogle Scholar
  51. 51.
    Scheiflinger F, Dorner F, Falkner FG (1992) Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proc Natl Acad Sci U S A 89(21):9977–9981CrossRefGoogle Scholar
  52. 52.
    Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectors - insertion of the thymidine kinase gene from herpes-simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci-Biol 79(16):4927–4931.  https://doi.org/10.1073/pnas.79.16.4927CrossRefGoogle Scholar
  53. 53.
    Mackett M, Smith GL, Moss B (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79(23):7415–7419CrossRefGoogle Scholar
  54. 54.
    Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93(21):11341–11348CrossRefGoogle Scholar
  55. 55.
    Liu J, Wennier S, Reinhard M et al (2009) Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol 83(11):5933–5938.  https://doi.org/10.1128/JVI.00204-09CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Barrett JW, Shun Chang C, Wang G et al (2007) Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology 361(1):123–132.  https://doi.org/10.1016/j.virol.2006.11.015CrossRefPubMedGoogle Scholar
  57. 57.
    Bratke KA, McLysaght A, Rothenburg S (2013) A survey of host range genes in poxvirus genomes. Infect Genet Evol 14:406–425.  https://doi.org/10.1016/j.meegid.2012.12.002CrossRefPubMedGoogle Scholar
  58. 58.
    Barrett JW, Sypula J, Wang F et al (2007) M135R is a novel cell surface virulence factor of myxoma virus. J Virol 81(1):106–114.  https://doi.org/10.1128/JVI.01633-06CrossRefPubMedGoogle Scholar
  59. 59.
    Ogbomo H, Zemp FJ, Lun X et al (2013) Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One 8(6):e66825.  https://doi.org/10.1371/journal.pone.0066825CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Liu J, McFadden G (2015) SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses. J Virol 89(3):1925–1931.  https://doi.org/10.1128/JVI.02262-14CrossRefPubMedGoogle Scholar
  61. 61.
    Stewart L, Burgin AB (2005) Whole gene synthesis: a gene-O-matic future. Front Drug Des Discov 1(1):297–341.  https://doi.org/10.2174/1574088054583318CrossRefGoogle Scholar
  62. 62.
    Eindhoven T (2015) The Cloning Guide.80Google Scholar
  63. 63.
    Katzen F (2007) Gateway((R)) recombinational cloning: a biological operating system. Expert Opin Drug Discov 2(4):571–589.  https://doi.org/10.1517/17460441.2.4.571CrossRefPubMedGoogle Scholar
  64. 64.
    Liang X, Peng L, Baek CH et al (2013) Single step BP/LR combined Gateway reactions. BioTechniques 55(5):265–268.  https://doi.org/10.2144/000114101CrossRefPubMedGoogle Scholar
  65. 65.
    Mohamed MR, Rahman MM, Lanchbury JS et al (2009) Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc Natl Acad Sci U S A 106(22):9045–9050.  https://doi.org/10.1073/pnas.0900452106CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Liu J, Wennier S, Zhang L et al (2011) M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells. J Virol 85(7):3270–3282.  https://doi.org/10.1128/JVI.02243-10CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Smallwood SE, Rahman MM, Werden SJ et al (2011) Production of Myxoma virus gateway entry and expression libraries and validation of viral protein expression. Curr Protoc Microbiol Chapter 14:Unit 14A 12.  https://doi.org/10.1002/9780471729259.mc14a02s21CrossRefGoogle Scholar
  68. 68.
    Broyles SS (2003) Vaccinia virus transcription. J Gen Virol 84(Pt 9):2293–2303.  https://doi.org/10.1099/vir.0.18942-0CrossRefPubMedGoogle Scholar
  69. 69.
    Yang Z, Maruri-Avidal L, Sisler J et al (2013) Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters. Virology 447(1–2):213–220.  https://doi.org/10.1016/j.virol.2013.09.007CrossRefPubMedGoogle Scholar
  70. 70.
    Keck JG, Baldick CJ, Moss B (1990) Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell 61(5):801–809CrossRefGoogle Scholar
  71. 71.
    Davison AJ, Moss B (1989) Structure of vaccinia virus early promoters. J Mol Biol 210(4):749–769CrossRefGoogle Scholar
  72. 72.
    Davison AJ, Moss B (1989) Structure of vaccinia virus late promoters. J Mol Biol 210(4):771–784CrossRefGoogle Scholar
  73. 73.
    Skinner MA, Laidlaw SM, Eldaghayes I et al (2005) Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 4(1):63–76.  https://doi.org/10.1586/14760584.4.1.63CrossRefPubMedGoogle Scholar
  74. 74.
    Chakrabarti S, Sisler JR, Moss B (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23(6):1094–1097CrossRefGoogle Scholar
  75. 75.
    Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E et al (2015) The evolution of poxvirus vaccines. Viruses 7(4):1726–1803.  https://doi.org/10.3390/v7041726CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Cochran MA, Puckett C, Moss B (1985) In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol 54(1):30–37PubMedPubMedCentralGoogle Scholar
  77. 77.
    Thomas DL, Doty R, Tosic V et al (2011) Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother 60(10):1461–1472.  https://doi.org/10.1007/s00262-011-1045-zCrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Weir JP, Moss B (1987) Determination of the promoter region of an early vaccinia virus gene encoding thymidine kinase. Virology 158(1):206–210.  https://doi.org/10.1016/0042-6822(87)90254-6CrossRefPubMedGoogle Scholar
  79. 79.
    Baldick CJ Jr, Moss B (1993) Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes. J Virol 67(6):3515–3527PubMedPubMedCentralGoogle Scholar
  80. 80.
    Hagen CJ, Titong A, Sarnoski EA et al (2014) Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication. Virus Res 181:43–52.  https://doi.org/10.1016/j.virusres.2013.12.033CrossRefPubMedGoogle Scholar
  81. 81.
    Senkevich TG, Ward BM, Moss B (2004) Vaccinia virus A28L gene encodes an essential protein component of the virion membrane with intramolecular disulfide bonds formed by the viral cytoplasmic redox pathway. J Virol 78(5):2348–2356CrossRefGoogle Scholar
  82. 82.
    Hammond JM, Oke PG, Coupar BE (1997) A synthetic vaccinia virus promoter with enhanced early and late activity. J Virol Methods 66(1):135–138CrossRefGoogle Scholar
  83. 83.
    Rice AD, Gray SA, Li Y et al (2011) An efficient method for generating poxvirus recombinants in the absence of selection. Viruses 3(3):217–232.  https://doi.org/10.3390/v3030217CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Yao XD, Evans DH (2003) High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells. J Virol 77(13):7281–7290.  https://doi.org/10.1128/Jvi.77.13.7281-7290.2003CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Di Lullo G, Soprana E, Panigada M et al (2010) The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J Virol Methods 163(2):195–204.  https://doi.org/10.1016/j.jviromet.2009.09.016CrossRefPubMedGoogle Scholar
  86. 86.
    Franke CA, Rice CM, Strauss JH et al (1985) Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants. Mol Cell Biol 5(8):1918–1924.  https://doi.org/10.1128/Mcb.5.8.1918CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Zhou J, Crawford L, Sun XY et al (1991) The hygromycin-resistance-encoding gene as a selection marker for vaccinia virus recombinants. Gene 107(2):307–312CrossRefGoogle Scholar
  88. 88.
    Falkner FG, Moss B (1988) Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62(6):1849–1854PubMedPubMedCentralGoogle Scholar
  89. 89.
    Isaacs SN, Kotwal GJ, Moss B (1990) Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. Virology 178(2):626–630CrossRefGoogle Scholar
  90. 90.
    Lorenzo MM, Blasco R (1998) PCR-based method for the introduction of mutations in genes cloned and expressed in vaccinia virus. BioTechniques 24(2):308–313CrossRefGoogle Scholar
  91. 91.
    Wong YC, Lin LCW, Melo-Silva CR et al (2011) Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. J Virol Methods 171(1):295–298.  https://doi.org/10.1016/j.jviromet.2010.11.003CrossRefPubMedGoogle Scholar
  92. 92.
    Guo ZS, Liu Z, Sathaiah M et al (2017) Rapid generation of multiple loci-engineered marker-free poxvirus and characterization of a clinical-grade oncolytic vaccinia virus. Mol Ther Methods Clin Dev 7:112–122.  https://doi.org/10.1016/j.omtm.2017.09.007CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Dambach MJ, Trecki J, Martin N et al (2006) Oncolytic viruses derived from the γ34. 5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther 13(5):891–898CrossRefGoogle Scholar
  94. 94.
    Rintoul JL, Wang J, Gammon DB et al (2011) A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS One 6(9):e24643.  https://doi.org/10.1371/journal.pone.0024643CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Grosenbach DW, Jordan R, Hruby DE (2011) Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Futur Virol 6(5):653–671.  https://doi.org/10.2217/fvl.11.27CrossRefGoogle Scholar
  96. 96.
    Olson VA, Smith SK, Foster S et al (2014) In vitro efficacy of brincidofovir against variola virus. Antimicrob Agents Chemother 58(9):5570–5571.  https://doi.org/10.1128/AAC.02814-14CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Trost LC, Rose ML, Khouri J et al (2015) The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease. Antivir Res 117:115–121.  https://doi.org/10.1016/j.antiviral.2015.02.007CrossRefPubMedGoogle Scholar
  98. 98.
    Guimaraes AP, de Souza FR, Oliveira AA et al (2015) Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox. Eur J Med Chem 91:72–90.  https://doi.org/10.1016/j.ejmech.2014.09.099CrossRefPubMedGoogle Scholar
  99. 99.
    Lederman ER, Davidson W, Groff HL et al (2012) Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 206(9):1372–1385.  https://doi.org/10.1093/infdis/jis510CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Vora S, Damon I, Fulginiti V et al (2008) Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 46(10):1555–1561.  https://doi.org/10.1086/587668CrossRefPubMedGoogle Scholar
  101. 101.
    Adelfinger M, Bessler S, Frentzen A et al (2015) Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF single-chain antibody for canine cancer therapy. Viruses 7(7):4075–4092.  https://doi.org/10.3390/v7072811CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Patil SS, Gentschev I, Nolte I et al (2012) Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 10:3.  https://doi.org/10.1186/1479-5876-10-3CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Paszkowski P, Noyce RS, Evans DH (2016) Live-cell imaging of vaccinia virus recombination. PLoS Pathog 12(8):e1005824.  https://doi.org/10.1371/journal.ppat.1005824CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Villa NY, Bartee E, Mohamed MR et al (2010) Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology 401(2):266–279.  https://doi.org/10.1016/j.virol.2010.02.027CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Fang Q, Yang L, Zhu W et al (2005) Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 335(2):242–251.  https://doi.org/10.1016/j.virol.2005.02.014CrossRefPubMedGoogle Scholar
  106. 106.
    Henderson B (1996) In: Ausubel F, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K (eds) Short protocols in molecular biology, 3rd edn. John Wiley and Sons, Chichester xxxii+ 700 pages,£ 6.00 (1995). Wiley Online LibraryGoogle Scholar
  107. 107.
    Liu J, Wennier S, Moussatche N et al (2012) Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits. J Virol 86(9):5371–5375.  https://doi.org/10.1128/jvi.06933-11CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Microbiology and ImmunologyUniversity of Arkansas for Medical Sciences (UAMS)Little RockUSA
  2. 2.The Center for Microbial Pathogenesis and Host Inflammatory ResponsesUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations